ProMetic Life Sciences Inc. (PLI) Stock Rating Reaffirmed by BLOOM BURTON&CO

ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “hold” rating reiterated by research analysts at BLOOM BURTON&CO in a research report issued to clients and investors on Thursday.

PLI has been the topic of a number of other reports. TD Securities reaffirmed a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Scotiabank restated an “outperform” rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a research report on Thursday. Royal Bank Of Canada reiterated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Finally, CIBC dropped their price target on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) remained flat at $3.10 during trading on Thursday. The stock had a trading volume of 131,316 shares. The stock’s 50-day moving average price is $2.93 and its 200-day moving average price is $3.01. ProMetic Life Sciences has a 52-week low of $1.67 and a 52-week high of $3.62. The company’s market capitalization is $1.87 billion.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.